Last $1.07 USD
Change Today +0.02 / 1.90%
Volume 2.6M
PVCT On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

provectus biopharmaceutica-a (PVCT) Snapshot

Open
$1.08
Previous Close
$1.05
Day High
$1.09
Day Low
$1.05
52 Week High
01/23/14 - $6.03
52 Week Low
05/27/14 - $0.30
Market Cap
189.0M
Average Volume 10 Days
1.6M
EPS TTM
$-0.20
Shares Outstanding
176.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROVECTUS BIOPHARMACEUTICA-A (PVCT)

Related News

No related news articles were found.

provectus biopharmaceutica-a (PVCT) Related Businessweek News

No Related Businessweek News Found

provectus biopharmaceutica-a (PVCT) Details

Provectus Biopharmaceuticals, Inc., a development-stage biopharmaceutical company, is engaged in developing pharmaceuticals for oncology and dermatology indications. The company’s product line includes PV-10, which has completed Phase II study for metastatic melanoma; completed a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, as well as initiated a Phase I feasibility study to detect immune cell infiltration into melanomas. It is also developing PH-10 that is in Phase IIc randomized study for the treatment of psoriasis; and has completed Phase II study for the treatment of atopic dermatitis. In addition, the company develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. Further, it is developing over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products. Additionally, Provectus Biopharmaceuticals, Inc. develops medical device technologies for markets comprising cosmetic treatments, such as reduction of wrinkles and elimination of spider veins, and other cosmetic blemishes; and therapeutic uses, including photoactivation of PH-10, other prescription drugs, and non-surgical destruction of certain skin cancers. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

4 Employees
Last Reported Date: 08/7/14
Founded in 2002

provectus biopharmaceutica-a (PVCT) Top Compensated Officers

Chairman, Chief Executive Officer, Chief Exec...
Total Annual Compensation: $500.0K
President, Director, President of Xantech and...
Total Annual Compensation: $500.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $500.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2013.

provectus biopharmaceutica-a (PVCT) Key Developments

Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd

Provectus Biopharmaceuticals, Inc. announced that it entered into a Memorandum of Understanding ("MOU") with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), and Sinopharm A-THINK Pharmaceutical Co. Ltd. ("Sinopharm A-THINK"). The key component of the MOU provides that Sinopharm-CSIPI and Sinopharm A-THINK desire to obtain an exclusive license to commercialize PV-10 within [the People's Republic of] China territory, and PVCT is willing to grant such license to Sinopharm. During the next three months, the parties will seek to enter into a definitive licensing contract, subject to additional negotiation, due diligence, and any required regulatory and corporate approvals. The parties will further address the details of the license; the use of the technology from Provectus to Sinopharm A-THINK in China; the process for commercialization; and payments to Provectus (upfront, milestone and royalties). Provectus intends to manufacture PV-10 in the USA and Sinopharm A-THINK will distribute PV-10 in China. The MOU, which is governed by Chinese law, stems from negotiations led by Network 1 Financial Securities, a financial advisor to Provectus. The parties met at the headquarters of Sinopharm-CSIPI in Shanghai, China. In attendance were the senior management members of Sinopharm Group, as well as senior Provectus personnel. Provectus presented clinical and nonclinical data of its drug, PV-10. The experts and scientists from Sinopharm-CSIPI and Sinopharm A-THINK had an extensive and substantial discussion with the Provectus team. The MOU provides that the parties agreed that PV-10 is an advanced innovative drug representing the oncology research trend worldwide, [which] will provide extensive economic and social benefits to [the Chinese] market. In addition, the MOU says that all parties recognized the achievements gained during PV-10's clinical trial on melanoma, breast cancer and cancer of liver, plus the systematic effect on human immune efficacy, and PV-10 could be applied to other indications such as lung cancer, pancreatic cancer, prostate cancer and kidney cancer. The MOU contains customary provisions regarding confidential information, publicity, and intellectual property, and is non-binding upon the parties (except for certain non-material provisions). The MOU shall continue in effect until the earliest of the replacement of the MOU with a definitive agreement, one month prior written notice by either Provectus or Sinopharm, or ninety days from the signing of the MOU.

Provectus Biopharmaceuticals, Inc. - Special Call

To update the market in general and shareholders in particular about developments at the company

Brower Piven Commences Class Action Lawsuit Against Provectus Biopharmaceuticals, Inc

The securities litigation law firm of Brower Piven, A Professional Corporation, announced that a class action lawsuit has been commenced in the United States District Court for the Middle District of Tennessee on behalf of purchasers of Provectus Biopharmaceuticals, Inc. publicly traded securities during the period between December 17, 2013 and May 22, 2014, inclusive, and informs investors who wish to become proactively involved in the litigation that they have until July 28, 2014 to seek appointment as lead plaintiff. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period the true prospects for PV-10 and that new skin cancer drugs being developed may have rendered PV-10 obsolete.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PVCT:US $1.07 USD +0.02

PVCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PVCT.
View Industry Companies
 

Industry Analysis

PVCT

Industry Average

Valuation PVCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROVECTUS BIOPHARMACEUTICA-A, please visit www.pvct.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.